Products
MSDC-0160 146062-49-9
1.Inquiries will be replied within 24 hours |
2.We could supply various packages as you required |
3.To protect the profit of our agents, price will not show on website, please send inquiries to get the price. |
4.Fast delivery, goods arrive your office within 3 to 5 days |
5.Please click "Inquiry" or "Email" below to get the price |
|
|
||||||
|
C19 H18 N2 O4 S |
|
|||||
|
370.42 |
|
in stock | ||||
|
146062-49-9 |
|
98%+ |
Introduction
MSDC-0160 is a prototype mTOT-modulating insulin sensitizer being studied to treat diabetes and Alzheimer's disease. Phase 2.
MSDC-0160 reduces resistance in the insulin/IGF-1 signaling pathway and restores IGF-1-induced Akt and GSK-3 phosphorylation. MSDC-0160 in combination with IGF-1 and 8 mM glucose increases β-cell specific gene expression of insulin, pdx1, nkx6.1, and nkx2.2, and maintains insulin content without altering glucose-stimulated insulin secretion. Furthermore, MSDC-0160 promotes human β-cell differentiation and reduces the expression of markers of apoptosis.
MSDC-0160 reduces resistance in the insulin/IGF-1 signaling pathway and restores IGF-1-induced Akt and GSK-3 phosphorylation. MSDC-0160 in combination with IGF-1 and 8 mM glucose increases β-cell specific gene expression of insulin, pdx1, nkx6.1, and nkx2.2, and maintains insulin content without altering glucose-stimulated insulin secretion. Furthermore, MSDC-0160 promotes human β-cell differentiation and reduces the expression of markers of apoptosis.